

Hepatitis A Outbreak Associated with Cuba — Florida, June 2024–February 2026

Natnari Natalie Linwong, MD^{1,2}; Marie K. Etienne, MPH³; Anthoni Llau, PhD³; Scot Menke, MPH⁴; Shannon Patelsky, MPH⁵; Natalia Cano, MPH⁶; Timothy J. Doyle, PhD^{1,7}

Abstract

Beginning in early 2025, Florida Department of Health (FDOH) staff members noted an unusually high proportion of reported hepatitis A cases among travelers who had recently been in Cuba. Hepatitis A outbreaks have been reported in Cuban local news media; however, government reports are limited. FDOH investigated to characterize hepatitis A cases associated with travel to Cuba among Florida residents (including four patients who had recently emigrated from Cuba). FDOH found that among 249 confirmed hepatitis A cases identified during June 2024–February 2026, 76 (31%) patients reported recent travel to Cuba before symptom onset. Among patients with Cuba travel–associated hepatitis A, the median age was 39 years, 70% were male, 87% were White, and 92% were Hispanic or Latino. Patients lived in 13 (19%) of Florida's 67 counties. Among 29 patients who completed supplemental travel questionnaires, 55% had visited Havana; other travel destinations included eight additional Cuban provinces. Hepatitis A virus (HAV) genotyping of 18 isolates from unique patients with outbreak-associated cases identified 15 (83%) isolates that matched HAV genotype IA outbreak strain 1, two (11%) that matched IB strain 1, and one (6%) that matched IA strain 2. These findings are consistent with what would be expected were widespread hepatitis A transmission affecting multiple regions of Cuba. CDC recommends hepatitis A vaccination or receipt of immune globulin before travel to Cuba. Providers' consideration of hepatitis A among patients returning from Cuba who have hepatitis A–compatible signs and symptoms, together with elicitation of a detailed travel history, might aid diagnosis of Cuba travel–associated cases.

Investigation and Results

Reports of Hepatitis A in Cuba

Since 2024, Cuban news media have reported hepatitis A outbreaks in multiple provinces related to drinking water contamination associated with disruptions in sanitation and utility systems (1,2). However, official Cuban national surveillance data have not been publicly disseminated. In December 2024, the Ministry of Public Health of Cuba issued a tourist alert regarding increased cases of hepatitis A (3). In early 2025, FDOH observed that a high proportion of recent hepatitis A cases reported in Florida occurred among patients who had traveled to Cuba during their exposure periods (15–50 days before symptom onset), and in August 2025, the U.S. Embassy in Cuba issued a health alert regarding increased numbers of cases in Havana (4).

Florida's Cuban-American Population

Florida is home to approximately 1.8 million Cuban Americans, who account for 8% of the state's population (5). Many Florida residents travel to Cuba regularly to visit family and friends. Considering these connections and the limited availability of

INSIDE

- 573 Environmental Investigation of a *Campylobacteriosis* Outbreak Among Wedding Attendees — York County, Pennsylvania, 2025
- 576 Notes from the Field: The First 100 Days of Five Ebola Outbreaks — Democratic Republic of the Congo, Uganda, and West Africa, 2007–2026
- 579 QuickStats

Continuing Education examination available at
https://www.cdc.gov/mmwr/mmwr_continuingEducation.html



**U.S. DEPARTMENT OF
HEALTH AND HUMAN SERVICES**
CENTERS FOR DISEASE
CONTROL AND PREVENTION

information regarding the hepatitis A outbreaks in Cuba, FDOH investigated to characterize cases associated with travel to Cuba.

Public Health Investigation of Hepatitis A Cases in Florida

Hepatitis A is a reportable condition in Florida. FDOH uses the [national surveillance case definition for hepatitis A](#). FDOH staff members investigate all reported hepatitis A cases by interviewing patients and reviewing medical records to obtain demographic information, document the clinical course, identify risk factors for infection (e.g., recent history of travel, incarceration, housing status, substance use, sexual activity, and consumption of certain foods), and identify close contacts for possible prophylaxis and follow-up.

HAV Genotyping

For all patients whose cases were reported and met the hepatitis A surveillance case definition, medical providers and commercial laboratories were asked to forward available blood samples to FDOH's Bureau of Public Health Laboratories (BPHL) for HAV genotyping. BPHL performed genotyping based on the 349-nucleotide VP1-P2B junction region of the HAV genome (6). Next-generation sequencing was conducted on specimens, and data were uploaded to CDC's Global Hepatitis Outbreak Surveillance Technology (GHOST) platform* and compared with an HAV genetic sequence reference set to identify matching strains (7).

*CDC developed the GHOST system to characterize viral genotypes and transmission links among cases with hepatitis C virus infection in outbreak settings; the content is also applicable to hepatitis A infections in outbreak settings. [Molecular Epidemiology of HCV Infection | Viral Hepatitis | CDC](#)

Cuba Travel–Associated Outbreak Case Definition

FDOH created an outbreak case definition for hepatitis A cases associated with travel to Cuba. A Cuba travel–associated hepatitis A outbreak case was defined as a hepatitis A infection in a Florida resident meeting the surveillance case definition for confirmed hepatitis A, with symptom onset during June 1, 2024–February 28, 2026, and who met at least one of the following criteria: 1) known history of travel to or emigration from Cuba 15–50 days before symptom onset, 2) gene sequencing data indicating genotype 1A outbreak strain 1, or 3) epidemiologic linkage to a confirmed outbreak case. The gene sequencing criterion was included because FDOH observed that several cases associated with travel to Cuba had matching genotype 1A strain 1, which had not previously been identified in Florida or reported in GHOST, and which suggested a common epidemiologic origin.

Supplemental Questionnaire Data

In addition to the routine epidemiologic investigation conducted for all hepatitis A cases in Florida, additional travel information was obtained for patients with cases meeting the Cuba travel–associated outbreak case definition in the three southeastern counties with the highest numbers of outbreak-associated cases (Broward, Miami-Dade, and Palm Beach). These three counties accounted for 59 (75%) of the 79 cases that met the outbreak case definition. FDOH staff members in these counties obtained additional details from patients regarding travel to Cuba using a standardized, supplemental,

The *MMWR* series of publications is published by the Office of Science, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30329-4027.

Suggested citation: [Author names; first three, then et al., if more than six.] [Report title]. *MMWR Morb Mortal Wkly Rep* 2026;75:[inclusive page numbers].

Centers for Disease Control and Prevention

Erica Schwartz, MD, MPH, JD, *Director*
Jennifer A. Shuford, MD, MPH, *Deputy Director and Chief Medical Officer*
Althea Grant-Lenzy, PhD, MSS, *Director, Office of Science*

MMWR Editorial and Production Staff (Weekly)

Jacqueline Gindler, MD, <i>Editor</i>	Terraye M. Starr,	Lowery Johnson,
Mary Dott, MD, MPH, <i>Online Editor</i>	<i>Acting Lead Health Communication Specialist</i>	<i>Health Communication Specialist</i>
Terisa F. Rutledge, <i>Managing Editor</i>	Alexander J. Gottardy,	Will Yang, MA,
Catherine B. Lansdowne, MS,	Maureen A. Leahy,	<i>Visual Information Specialist</i>
<i>Lead Technical Writer-Editor</i>	<i>Visual Information Specialists</i>	
Stacy Simon, MA, Morgan Thompson,	Quang M. Doan, MBA,	
Suzanne Webb, PhD, MA,	Phyllis H. King, Moua Yang,	
<i>Technical Writer-Editors</i>	<i>Information Technology Specialists</i>	

MMWR Editorial Board

Matthew L. Boulton, MD, MPH	Timothy F. Jones, MD, <i>Chairman</i>	Patrick L. Remington, MD, MPH
Carolyn Brooks, ScD, MA	David W. Fleming, MD	Carlos Roig, MS, MA
Virginia A. Caine, MD	William E. Halperin, MD, DrPH, MPH	William Schaffner, MD
Jonathan E. Fielding, MD, MPH, MBA	Jewel Mullen, MD, MPH, MPA	Morgan Bobb Swanson, MD, PhD
	Jeff Niederdeppe, PhD	
	Patricia Quinlisk, MD, MPH	

telephone-administered questionnaire. Patients were asked about their method of travel, where and with whom they stayed, sources of drinking water, and whether they had heard reports of hepatitis A while in Cuba. Among the 59 patients from the three most affected counties, 29 (49%) patients completed the supplemental questionnaire; the others either refused or could not be reached. Questionnaires were administered during December 2025–February 2026 to patients whose cases had previously been reported and investigated as well as to patients with newly reported cases. This activity was reviewed by CDC, deemed not research, and conducted consistent with applicable federal law and CDC policy.[†]

Characteristics of Patients with Hepatitis A

A total of 249 confirmed cases of hepatitis A with illness onset during June 1, 2024–February 28, 2026, were reported to FDOH. Among these, 118 (47%) patients reported international travel during their exposure period, including 76 (31%) who had traveled to Cuba. Three additional cases were linked to the outbreak through gene sequencing data or epidemiological linkage. Overall, 79 cases (32%) met the outbreak case definition. Among patients with outbreak-associated hepatitis A, the median age was 39 years, 70% were male, 87% were White, and 92% were Hispanic or Latino; 72% were hospitalized and no deaths occurred (Table). Outbreak-associated cases occurred among residents of 13 counties in Florida; 46 (58%) of the 79 patients who met the outbreak case definition lived in Miami-Dade County (Figure 1).

History of Travel to Cuba

Among the 79 outbreak-associated cases, 64 (81%) patients had recently visited Cuba with known dates of travel, eight (10%) had recent travel to Cuba during their exposure periods but with exact travel dates unknown, and four (5%) had recently emigrated from Cuba. Two (3%) patients who could not be interviewed had an unknown travel history but were included based on gene sequencing data that matched the predominant HAV strain associated with travel to Cuba. One (1%) patient had no recent travel history but was epidemiologically linked to a confirmed case in a household contact in Florida who had traveled to Cuba. No other epidemiologic linkages were identified among cases. Among 64 patients with known travel dates, the median length of stay in Cuba was 11 days (IQR = 6–26 days). Seven of 76 (9%) patients reported that while in Cuba, each was exposed to a family member who had received a hepatitis A diagnosis. Risk factors for HAV infection in addition to travel to Cuba were identified among three patients: two male patients (3%) reported having had sex

TABLE. Characteristics of hepatitis A cases associated with Cuba — Florida, June 2024–February 2026

Characteristic (no. with available information)	No. (%)
Age, yrs (79)	
Median (IQR)	39 (31–51)
Sex (79)	
Female	24 (30.4)
Male	55 (69.6)
Race (78)	
Asian	1 (1.3)
Black or African American	2 (2.6)
White	68 (87.2)
Other	7 (9.0)
Ethnicity (78)	
Hispanic or Latino	72 (92.3)
Not Hispanic or Latino	6 (7.7)
Emergency department visit (79)	
Yes	60 (75.9)
No	19 (24.1)
Hospitalized (78)	
Yes	56 (71.8)
No	22 (28.2)
Genotype and strain (18)	
IA outbreak strain 1	15 (83.3)
IB strain 1	2 (11.1)
IA strain 2	1 (5.6)
Length of stay in Cuba, days (64)	
Median (IQR)	11 (6–26)
Mode of travel (29)	
Commercial flight	23 (79.3)
Charter flight	6 (20.7)
Province of overnight stay (29)*	
La Habana	16 (55.2)
Villa Clara	3 (10.3)
Matanzas	3 (10.3)
Mayabeque	2 (6.9)
Pinar del Río	2 (6.9)
Sancti Spiritus	2 (6.9)
Holguín	1 (3.4)
Camagüey	1 (3.4)
Granma	1 (3.4)
Persons traveler stayed with (28)	
Only family or friends	26 (92.9)
Both family or friends and hotels or guesthouses	2 (7.1)
Drinking water sources while in Cuba (29)*	
Tap	12 (41.4)
Bottled	20 (69.0)
Ice	4 (13.8)
Boiled or filtered	4 (13.8)
Heard reports of hepatitis A while in Cuba (29)	
Yes	13 (44.8)
No	16 (55.2)


* Because multiple responses were allowed, the number of responses does not match the number of respondents.

with men, and one patient (1%) reported having had household contact with another patient in Florida who had traveled to Cuba. No patients reported experience with homelessness, incarceration, or recreational drug use during their potential exposure period.

Supplemental questionnaires provided additional details regarding travel to Cuba. A total of 16 of 29 respondents (55%)

[†] 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.

FIGURE 1. Number of outbreak-associated hepatitis A cases* among Florida residents recently in Cuba, by county — June 2024–February 2026



* The total number of outbreak-associated cases per county were Brevard, two; Broward, five; Collier, two; Duval, one; Flagler, two; Hernando, one; Hillsborough, three; Lee, six; Manatee, one; Miami-Dade, 46; Osceola, one; Palm Beach, eight; and St. Lucie, one. The number of cases associated with the dominant hepatitis A virus genotype IA outbreak strain 1 were one each in Brevard, Lee, and Osceola counties, and six each in Miami-Dade and Palm Beach counties.

stayed in Havana, and 14 (48%) stayed in other provinces (one stayed in both Havana and another province). Of 28 respondents who provided additional information about where they stayed, 26 (93%) stayed only with family and friends. Twelve (41%) of 29 respondents reported drinking tap water, 20 (69%) reported drinking bottled water, four (14%) reported drinking boiled or filtered water, and four (14%) reported consuming ice (several respondents reported that they consumed water from multiple sources). Overall, 13 (45%) of 29 respondents had heard reports of hepatitis A cases or outbreaks from family or friends while in Cuba.

Gene Sequencing

Gene sequencing was completed for isolates from 18 outbreak-associated cases[§] from five counties (Brevard, Lee, Miami-Dade, Osceola, and Palm Beach). Of these cases, 15 (83%) matched HAV genotype IA outbreak strain 1, two (11%) matched genotype IB strain 1, and one (6%) matched IA strain 2 (Figure 2).

Discussion

During 2025, Florida public health officials noticed that numerous hepatitis A cases were occurring among persons with

[§] Sixteen of these 18 cases occurred among the 76 persons who reported travel to Cuba; the other two cases occurred among persons who had unknown travel history but met the outbreak case definition because their genotyping results matched the dominant outbreak strain.

recent travel to Cuba. Because of the large Cuban-American population in Florida, an investigation was conducted that found that 76 of 249 (31%) reported hepatitis A cases during June 2024–February 2026 were associated with travel to Cuba; the investigation connected three additional cases with the outbreak by matching genotype or epidemiologic linkage. Among outbreak cases for which gene sequencing data were available, 83% matched genotype IA outbreak strain 1, which was first reported in GHOST and identified in an outbreak-associated case in Florida in February 2025. Two additional HAV strains were observed: a second genotype IA strain in a single case, and an additional HAV strain in two cases identified as genotype IB, indicating no common chain of transmission from the other genotyped cases. The gene sequences from cases associated with travel to Cuba did not match any sequence patterns observed in Florida before this outbreak. Sequence patterns from Cuba were not available.

The high proportion of hepatitis A cases linked to travel from a single country during the analysis period differs from historical patterns in Florida. During 2010–2017, 34% of hepatitis A cases in Florida were associated with international travel, compared with 47% observed in the analysis period, and 32% associated with Cuba. During 2018–2019, a period characterized by a large hepatitis A outbreak associated with person-to-person transmission, only 3.3% of cases were associated with international travel, and cases with international travel were more likely to be associated with unique HAV nucleotide sequence patterns, rather than matching strains indicative of a common origin (6).


These findings indicate that an outbreak of hepatitis A in Cuba, occurring over several months, has affected Florida residents with recent travel history to Cuba. The proportion of hepatitis A cases among Florida residents reporting travel to Cuba exceeds historical norms, and among nearly all patients with history of travel to Cuba, no other risk factors for HAV infection were identified. Except for one episode of household transmission, no other evidence of secondary spread in Florida was found.

The risk for hepatitis A among travelers to Cuba is ongoing. Additional cases in Florida residents have been identified since March 2026, with exposures in Cuba as recently as August 2026.

Limitations

The findings in this report are subject to at least four limitations. First, whereas 79 outbreak-associated cases were reported in 13 counties, sequencing data were only available for 18 cases (23%), all of which occurred among residents of five counties. Second, supplemental questionnaires were completed for 37% of outbreak-associated cases from three counties; therefore, sequencing and questionnaire data might not be representative

FIGURE 2. Number of hepatitis A cases, by month of symptom onset and strain — Florida, June 2024–February 2026



Summary

What is already known about this topic?

Cuban news media have reported increased numbers of hepatitis A cases since 2024; however, official government reports about hepatitis A in Cuba have been limited.

What is added by this report?

During June 1, 2024–February 28, 2026, among 249 hepatitis A cases reported in Florida, 76 (31%) were associated with recent travel to Cuba. Among 18 genotyped cases, 15 shared a matching genotype 1A strain, consistent with a common origin.

What are the implications for public health practice?

Counseling on preventive measures including hepatitis A vaccination and immune globulin should be offered to travelers before planned trips to Cuba. Providers should consider hepatitis A among patients with clinically compatible symptoms who have recently been in Cuba.

of all outbreak-associated cases. Third, supplemental questionnaires were administered up to 18 months after illness and responses might have been subject to recall bias. Finally, because the exposure period for most patients included time spent in both Cuba and Florida, it cannot be confirmed that all HAV infections were acquired in Cuba.

Implications for Public Health Practice

This investigation found evidence of travel-associated hepatitis A among Florida residents who had recently returned from Cuba, where news media have reported increased numbers of hepatitis A cases since 2024. Based on these findings, eliciting a detailed travel history from patients with symptoms clinically compatible with hepatitis A and consideration of the possibility of hepatitis A among patients with recent travel history to

Cuba might help identify cases. For travelers receiving health care before traveling to Cuba, providers should review [CDC recommendations for hepatitis A vaccination and consider immune globulin for high-risk travelers](#) (adults aged >40 years, immunocompromised persons, and persons with chronic liver disease) departing within 2 weeks (8,9). Counseling may also be provided regarding risk factors and preventive measures, including food and water safety and hand hygiene.

Acknowledgments

Brian Buck, Janet Grajales, Nicolette Konze, Tracy Loewecke, Valeria Malo, Rafael Mendoza, Michaela Proffitt, Karen Thomas, staff members of county health departments and the Bureau of Public Health Laboratories, Florida Department of Health; patients and medical providers in Florida.

Corresponding author: Natnari Natalie Linwong, nlinwong@cdc.gov.

¹Bureau of Epidemiology, Florida Department of Health; ²Epidemic Intelligence Service, CDC; ³Miami-Dade County, Florida Department of Health, Miami, Florida; ⁴Palm Beach County, Florida Department of Health, West Palm Beach, Florida; ⁵Broward County, Florida Department of Health, Fort Lauderdale, Florida; ⁶Bureau of Public Health Laboratories, Florida Department of Health; ⁷Division of State and Local Readiness, Office of Readiness and Response, CDC.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

References

1. CiberCuba. Alert in Cienfuegos against hepatitis A outbreak due to contamination of drinking water with sewers. Valencia, Spain: CiberCuba; 2024. <https://en.cibercuba.com/noticias/2024-05-09-u1-e199854-s27061-nid281624-alerta-cienfuegos-brote-hepatitis-contaminacion-agua>
2. Fernandez O. Health alert in Matanzas as hepatitis outbreaks emerge across several municipalities. CubaHeadlines. April 5, 2026. <https://www.cubaheadlines.com/articles/324924>

3. Código San Luis.com. Alert in Cuba over hepatitis A outbreak [Spanish]. San Luis Potosí, Mexico; 2026. <https://codigosanluis.com/alerta-en-cuba-por-brote-de-hepatitis-a/>
4. US Embassy in Cuba. Event: hepatitis A health alert. Havana, Cuba: US Embassy in Cuba; 2025. <https://cu.usembassy.gov/health-alert-u-s-embassy-havana-cuba-august-27-2025/>
5. US Census Bureau. B03001 Hispanic or Latino origin by specific origin: American Community Survey, universe: total population, 2024: ACS 1-year estimates detailed tables. Suitland, MD: US Census Bureau; 2026. <https://data.census.gov/table/ACSDT1Y2024.B03001?q=B03001&g=040XX00US12>
6. Doyle TJ, Buck BH, Locksmith TJ, McGruder-Rawson BM, Khudyakov Y, Blackmore C. Genomic epidemiology of resurgent hepatitis A in Florida, 2018–2022. *J Infect Dis* 2025;232:943–52. PMID:40066809 <https://doi.org/10.1093/infdis/jiaf127>
7. Ramachandran S, Xia G-L, Dimitrova Z, et al. Changing molecular epidemiology of hepatitis A virus infection, United States, 1996–2019. *Emerg Infect Dis* 2021;27:1742–5. PMID:34013865 <https://doi.org/10.3201/eid2706.203036>
8. Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of hepatitis A virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices, 2020. *MMWR Recomm Rep* 2020;69(No. RR-5):1–38. PMID:32614811 <https://doi.org/10.15585/mmwr.rr6905a1>
9. Hofmeister MG, Weng MK. Hepatitis A. In: Halsey ES, Angelo KM, Barnett ED, et al., eds. *CDC Yellow Book, 2026 ed.: Health Information for International Travel*. Atlanta, GA: CDC; 2025. <https://www.ncbi.nlm.nih.gov/books/NBK620902/>

Environmental Investigation of a *Campylobacteriosis* Outbreak Among Wedding Attendees — York County, Pennsylvania, 2025

Rugiatu Z. Kamara, MBChB^{1,2}; Shanna Miko, DNP¹; Amy M. Kahler, MS¹; Alexis V. Roundtree^{1,3}; Haley J. McKeel¹; Yang Gao, PhD¹; Charlotte Lane¹; Kristina Zwolenik, MPH⁴; Kelly E. Kline, MPH⁵; Aaron Smee⁴; Olivia Fitzmaurice-Shean, MPH⁴; Bevin S. Durant Fidler, MPH⁴; Nicholas Cesari, MPH⁴; Shannon McGinnis, PhD⁴; Mia Catharine Mattioli, PhD¹

In early June 2025, approximately 80 persons attended a wedding at a venue in York County, Pennsylvania. Within 3 days, multiple attendees reported experiencing gastrointestinal illness. On June 23, the Pennsylvania Department of Health (PDOH) and the Pennsylvania Department of Agriculture (PDA) contacted CDC to request assistance after PDOH became aware of a laboratory-confirmed *Campylobacter jejuni* infection and reports of approximately 20 additional symptomatic attendees, with epidemiologic information implicating exposure to untreated spring water at the venue as a common exposure source. The focus of this report is on environmental inspection, testing, and identification of pathogens. This activity was reviewed by CDC, deemed not research, and conducted consistent with applicable federal law and CDC policy.*

Investigation and Outcomes

Survey of Event Attendees

On June 30, PDOH sent a link to an online questionnaire to all wedding attendees to identify additional cases and characterize exposures. Because some attendees shared email addresses, the exact number of attendees who received the questionnaire could not be determined; however, 46 responses were received. Among these, 15 (33%) persons reported gastrointestinal illness 1–10 days after the event; however, no specific food item associated with illness was identified.

Use of On-Site Spring Water During the Event and Inspection of the Spring

The venue manager reported that the site normally relied on vendors to supply potable water and ice. However, after the vendor's bottled water supply was exhausted during the event, employees of the vendor began drawing water from a kitchen tap connected to an on-site spring for food preparation and beverage service; no signage identified the water as nonpotable.

An onsite inspection by PDOH and PDA officials identified substantial deficiencies at the spring, including 1) a broken springhouse roof allowing entry of debris and animal feces (Figure), 2) a nonfunctional ultraviolet treatment unit (inoperable for ≥2 months), 3) evidence of animal activity, and 4) proximity of the spring to a chicken coop and an area occupied by horses.

Testing of Water Samples

On July 9, PDOH and PDA officials collected paired large-volume (100-L) ultrafiltered and (500-mL) grab samples[†] from the spring and the kitchen tap (1); point-of-use ultraviolet filters[§] had been installed in the kitchen tap after the wedding but before sample collection. CDC's Environmental Microbiology and Engineering Laboratory analyzed samples for *Campylobacter* spp. (2), culturable fecal indicator bacteria (total coliforms and *Escherichia coli*), and microbial source tracking[¶] molecular markers targeting fecal contamination from birds and ruminants (3,4), potential reservoirs of *Campylobacter* organisms present on the property.

Culturable *Campylobacter* organisms were not recovered from any sample, but *Campylobacter* DNA was detected in both spring and tap water. Fecal indicator bacteria were markedly elevated in spring water (total coliforms >2,419.6 most probable number [MPN]/100 mL; *E. coli* 547.5 MPN/100 mL)** but undetectable at the tap, suggesting that point-of-use treatment reduced but did not eliminate detectable *Campylobacter* DNA. Source tracking markers for birds and ruminants were not detected at either site, leaving the source or sources of fecal contamination undetermined.

Preliminary Conclusions and Actions

Epidemiologic linkage of illness to spring-water consumption, environmental deficiencies at the spring, and detection of *Campylobacter* DNA and fecal indicator bacteria in the spring water support untreated spring water as the most likely outbreak source. Absence of culturable pathogens does not rule out prior contamination, because *Campylobacter* organisms can enter a viable but nonculturable state (5), and sampling occurred after symptom onset. After the investigation, the venue installed two point-of-use water filters, repaired the springhouse roof, and posted signage identifying water from spring-fed taps as nonpotable. State officials recommended that the venue improve communication with external vendors to prevent future use of the nonpotable water source for food preparation and drinking.

[†] A single discrete sample collected at a specific location to provide a measurement of contamination at a specific point in time.


[§] Ultraviolet treatment systems use ultraviolet light to disinfect water or reduce the number of harmful microorganisms in water.

[¶] Microbial source tracking uses tests that identify fecal bacteria linked to specific hosts to help determine where contamination in environmental water comes from.

** Measured using Environmental Protection Agency standard methods, [IDEXX Colilert-18](#), on 100-mL grab samples.

* 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.

FIGURE. Bottom of the spring that provided water to a wedding venue, and was associated with an outbreak of *Campylobacter jejuni* gastroenteritis, showing algal growth, pieces of the broken roof, and evidence of animal activity — York County, Pennsylvania, 2025



Photo/Pennsylvania Department of Health, 2025

Private springs are largely unregulated in the United States, and, in the absence of visible contamination, users might assume such water is safe. These findings suggest that timely environmental testing paired with epidemiologic investigation could improve source attribution and guide the development and implementation of remediation efforts at venues serving the public. Routine inspection and maintenance of untreated private water sources might reduce the risk for waterborne outbreaks.

Acknowledgments

Channing Greenland, Phillip Keener, Nicole Mundorf, Stefanie Smith, Pennsylvania Department of Agriculture Bureau of Food

Safety & Laboratory Services; the Pennsylvania Department of Environmental Protection, Bureau of Safe Drinking Water.

Corresponding author: Shanna Miko, rhu6@cdc.gov.

¹Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC; ²Epidemic Intelligence Service, CDC; ³Chenega Enterprise Systems & Solutions, LLC, Chesapeake, Virginia; ⁴Pennsylvania Department of Health, Bureau of Epidemiology; ⁵Pennsylvania Department of Agriculture, Bureau of Food Safety & Laboratory Services.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

References

Summary

What is already known about this topic?

Unregulated private springs are a known risk factor for gastrointestinal illness, including campylobacteriosis.

What is added by this report?

A *Campylobacter jejuni* outbreak among wedding attendees in Pennsylvania was linked to consumption of untreated water from an on-site spring; environmental sampling detected *Campylobacter* DNA in the spring and a tap it supplied. The broken springhouse roof permitted entry of debris and animal feces, an ultraviolet water treatment light was nonfunctional, and evidence of animal activity was observed in and around the spring.

What are the implications for public health practice?

Routine inspection and maintenance of untreated private springs and clear signage indicating whether water is potable might reduce the risk for waterborne outbreaks. Pairing environmental testing with epidemiology helps confirm exposure routes and can guide mitigation efforts.

1. US Environmental Protection Agency; CDC. Protocol for the collection of water samples for detection of pathogens and bioterrorism agents. Washington, DC: US Environmental Protection Agency, Office of Research and Development; Atlanta, GA: US Department of Health and Human Services, CDC; 2022. <https://nepis.epa.gov/Exe/ZyPDF.cgi/P1017HMN.PDF?Dockey=P1017HMN.PDF>
2. Lund M, Nordentoft S, Pedersen K, Madsen M. Detection of *Campylobacter* spp. in chicken fecal samples by real-time PCR. *J Clin Microbiol* 2004;42:5125–32. PMID:15528705 <https://doi.org/10.1128/jcm.42.11.5125-5132.2004>
3. Mieszkis S, Yala JF, Joubrel R, Gourmelon M. Phylogenetic analysis of *Bacteroidales* 16S rRNA gene sequences from human and animal effluents and assessment of ruminant faecal pollution by real-time PCR. *J Appl Microbiol* 2010;108:974–84. PMID:19735325 <https://doi.org/10.1111/j.1365-2672.2009.04499.x>
4. Weller D, Belias A, Green H, Roof S, Wiedmann M. Landscape, water quality, and weather factors associated with an increased likelihood of foodborne pathogen contamination of New York streams used to source water for produce production. *Front Sustain Food Syst* 2020;3:124. PMID:32440656 <https://doi.org/10.3389/fsufs.2019.00124>
5. Pitkänen T. Review of *Campylobacter* spp. in drinking and environmental waters. *J Microbiol Methods* 2013;95:39–47. PMID:23810971 <https://doi.org/10.1016/j.mimet.2013.06.008>

Notes from the Field

The First 100 Days of Five Ebola Outbreaks — Democratic Republic of the Congo, Uganda, and West Africa, 2007–2026

John Rossow, DVM^{1,2}; Thomas C. McHale, MD¹;
James Fuller, PhD¹; Delayo L. Zomahoun, MD¹; Amy Boore, PhD¹;
Lauren Erickson-Mamane, MPH¹; Hailey Whitmire, PharmD^{1,2};
Jaymin C. Patel, PhD^{1,2}; Dumazedier K. Kabasele, MD¹;
Noemi B. Hall, PhD¹; Issaka Kabore, MD¹; Billy Mutombo Mpianga, MPH¹;
Katrin S. Sadigh, MD¹; Amy Schuh, PhD^{1,2}; Tara Sealy, MS¹; Erika
Meyer, MPH¹; Elissa Meites, MD^{1,2}; Christine Atherstone, PhD¹;
Benjamin A. Dahl, PhD¹; CDC 2026 Ebola Response 100-Day
Reporting Team

On September 15, 2026, this report was posted as an MMWR Early Release on the MMWR website (<https://www.cdc.gov/mmwr>).

The first 100 days after identification of an outbreak are important to understanding transmission dynamics, impact of early public health interventions, and trajectory of potential future cases and deaths. A large Ebola disease outbreak in the Democratic Republic of the Congo (DRC), which has become the country's largest and deadliest, is ongoing. To better understand the current outbreak, this report compared metrics from the first 100 days of this outbreak with those of four past Ebola outbreaks. The historic outbreaks of Ebola disease selected for this comparison include the two largest (the 2014 outbreak in West Africa and a 2018 outbreak in DRC), and the only two previous outbreaks caused by Bundibugyo virus (the 2007 outbreak in Uganda and the 2012 outbreak in DRC). This activity was reviewed by CDC, deemed not research, and conducted consistent with applicable federal law and CDC policy.*

Investigation and Outcomes

Epidemiology of Five Outbreaks

2007 Bundibugyo virus disease outbreak, Uganda. Bundibugyo virus (species *Orthoebolavirus bundibugyoense*) was first identified in 2007 when it caused an outbreak of Ebola disease in Uganda (1). Fewer than 50 cases were identified during the first 100 days. [This outbreak](#) was limited to one district in Uganda (Bundibugyo district) and ended within 6 months, with a total of 131 confirmed, probable, and suspected cases and 42 (32%) deaths in persons with confirmed, probable, or suspected Ebola disease.

2012 Bundibugyo virus disease outbreak, DRC. The second known Bundibugyo virus outbreak (species *O. bundibugyoense*) occurred in 2012 in DRC; fewer than 50 cases were identified

during the first 100 days. [This outbreak](#) was limited to a single health zone in DRC (Isiro health zone, Haut-Uélé province) and ended within 6 months, with 62 confirmed, probable, and suspected cases and 34 (55%) deaths in persons with confirmed, probable, and suspected Ebola disease.

2014 Ebola virus disease outbreak, West Africa. In 2014, a large outbreak of Ebola virus disease caused by Ebola virus (species *Orthoebolavirus zairense*) was declared in Guinea. The initial outbreak report included 49 confirmed cases and 29 (59%) deaths. During the first 100 days (March 23–July 1, 2014), 759 suspected, probable, or confirmed cases and 467 (62%) deaths in persons with suspected, probable, or confirmed Ebola virus disease were reported from Guinea, Liberia, and Sierra Leone. This outbreak lasted 3 years, resulting in 28,610 cases and 11,308 (40%) deaths across 10 countries, becoming the largest Ebola disease outbreak in history (Figure) (2).

2018 Ebola virus disease outbreak, DRC. In 2018, a large outbreak of Ebola virus disease caused by Ebola virus (species *O. zairense*) occurred in DRC. During the first 103 days (August 1–November 11, 2018), 295 confirmed cases, 38 probable cases, and 171 (51%) deaths among persons with confirmed Ebola disease were reported across 14 health zones, primarily in eastern DRC. This outbreak resulted in 3,470 cases and 2,287 (66%) deaths over a period of 22 months (3).


2026 Bundibugyo virus disease outbreak, DRC. On May 14, 2026, an outbreak of Ebola disease caused by Bundibugyo virus (species *O. bundibugyoense*) was detected in DRC. The outbreak was declared on May 15, at which time DRC's Ministry of Health had identified 246 suspected cases and 76 suspected deaths, in addition to eight laboratory-confirmed cases and four deaths (4). During the outbreak's first 100 days (May 14–August 21, 2026), 5,458 confirmed cases and 2,606 (48%) deaths were reported across 57 of DRC's 519 health zones. Twenty-one probable or confirmed cases related to this outbreak were identified in Uganda, with limited local transmission, primarily among health care workers. One additional case, related to travel from DRC, was detected in France. During the first 100 days after detection, the current outbreak resulted in more cases than the other two largest Ebola disease outbreaks (7 and 16 times as many, respectively) (Figure). As of September 10, there has been no evidence of community transmission outside of DRC.

Implications and Next Steps

During the first 100 days after its detection, the 2026 Ebola outbreak has grown faster than any previous Ebola disease outbreak. The current outbreak also had more cases at the time of

*45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.

FIGURE. Cumulative number of Ebola disease cases,* by day, for the first 100 days (A) and the first year (B) of the outbreak — five Ebola outbreaks, Democratic Republic of the Congo, Uganda, and West Africa, 2007–2026



Abbreviations: BVD = Bundibugyo virus disease; DRC = Democratic Republic of the Congo; EVD = Ebola virus disease.

* The 2026 outbreak includes confirmed cases, the 2018 outbreak includes confirmed and probable cases, and the other outbreaks include confirmed, probable, and suspected cases of Ebola disease.

detection than did other outbreaks. Detection of large numbers of cases at the time an outbreak is first declared can indicate that multiple chains of transmission are occurring and that virus was circulating widely before it was recognized. Although many variables could affect its future trajectory, considering different Ebola outbreaks' first 100 days after detection and subsequent

case numbers, the 2026 outbreak appears to be demonstrating rapid growth that arouses concerns about ongoing spread.

The 2026 Ebola outbreak is proving to be challenging to control. This outbreak is occurring in areas affected by a protracted complex humanitarian emergency, including ongoing conflict involving armed groups, limited health care

Summary**What is already known about this topic?**

The Democratic Republic of the Congo (DRC) is experiencing its largest and deadliest Ebola disease outbreak, which is also the largest Ebola outbreak caused by Bundibugyo virus and the second largest Ebola outbreak worldwide.

What is added by this report?

The 2026 Ebola outbreak resulted in 5,458 confirmed cases and 2,606 deaths in DRC in the first 100 days after initial detection, indicating rapid growth. No previous Ebola outbreak caused >800 cases during the first 100 days.

What are the implications for public health practice?

This Ebola outbreak appears to be expanding faster than any previously documented Ebola outbreak, with seven times as many cases 100 days after initial detection than the 2014 Ebola outbreak in West Africa, the largest outbreak worldwide. Urgent implementation of public health interventions to identify cases, trace contacts, and limit transmission are needed to bring the outbreak under control.

CDC 2026 Ebola Response 100-Day Reporting Team

Andrew T. Boyd, CDC; Anna Bratcher, CDC; Vance Brown, CDC; Sean Browning, CDC; Jonathan Bryant-Genevier, CDC; Mary J. Choi, CDC; Arthalia Christie, CDC; Matthew Cole, CDC; Amber Dimer, CDC; Carrie Eggers, CDC; Sascha Ellington, CDC; Maestro Evans, CDC; Neil Gupta, CDC; Ruth Kallay, CDC; John Klena, CDC; Timothee Kinkela, CDC; Michael H. Kinzer, CDC; Veronica Lea, CDC; Emmanuel A. Mensah, CDC; Mpingulu Minlangu, CDC; Joel M. Montgomery, CDC; Michael Park, CDC; Nicole Paterson, CDC; Natalie Peters, CDC; Satish K. Pillai, CDC; Anne Purfield, CDC; Logan Ray, CDC; Jessica N. Ricaldi, CDC; Philip Ricks, CDC; Daniel Rosen, CDC; Dean Sayre, CDC; Rachel B. Slayton, CDC; Trevor Shoemaker, CDC; Ciara Sugarman, CDC; Leisel E. Talley, CDC; Alison M. Todres, CDC; Henry Walke, CDC; Emily Weston, CDC; Kristina Wielgosz, CDC; Emily Zielinski-Gutierrez, CDC.

Corresponding author: John Rossow, mwi4@cdc.gov.

¹CDC 2026 Ebola Response; ²U.S. Public Health Service, Rockville, Maryland.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No conflicts of interest were disclosed.

and other basic infrastructure, attacks on health workers, and community mistrust. These factors complicate the delivery of aid to affected communities despite substantial mobilization of response personnel and materials (e.g., laboratory equipment and personal protective equipment).

The current outbreak trajectory underscores the urgent need to continue to scale up evidence-based Ebola control measures, such as rapid case and contact identification, expansion of diagnostic capacity, improvement of infection prevention and control in health care settings, adoption of safe and dignified burials, strengthening of cross-border surveillance and coordination, and community engagement (2). Analysis of administrative health zone-level Ebola response indicators (5) might help identify operational gaps and guide targeted interventions.

Acknowledgments

Ministries of Health in the Democratic Republic of the Congo, Uganda, Guinea, Liberia, and Sierra Leone; CDC country office staff members; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, CDC; all CDC 2026 Ebola Response staff members, including the International Task Force, Epidemiology and Laboratory Task Force, and Data Analytics and Visualization Task Force.


References

1. Towner JS, Sealy TK, Khristova ML, et al. Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. *PLoS Pathog* 2008;4:e1000212. PMID:19023410 <https://doi.org/10.1371/journal.ppat.1000212>
2. Dahl BA, Kinzer MH, Raghunathan PL, et al. CDC's response to the 2014–2016 Ebola epidemic—Guinea, Liberia, and Sierra Leone. *MMWR Suppl* 2016;65(Suppl-3):12–20. PMID:27388930 <https://doi.org/10.15585/mmwr.su6503a3>
3. Aruna A, Mbala P, Minikulu L, et al. Ebola virus disease outbreak—Democratic Republic of the Congo, August 2018–November 2019. *MMWR Morb Mortal Wkly Rep* 2019;68:1162–5. <http://dx.doi.org/10.15585/mmwr.mm6850a3>
4. Zomahoun DL, Boyd MA, Honein MA, et al. Notes from the field: outbreak of Ebola disease caused by Bundibugyo virus—Democratic Republic of the Congo and Uganda, May 2026. *MMWR Morb Mortal Wkly Rep* 2026;75:293–4. PMID:42275261 <https://doi.org/10.15585/mmwr.mm7522e3>
5. Kabasele D, Meyer E, Kabore I, et al. Notes from the field: characteristics and monitoring of the 2026 outbreak of Ebola disease caused by Bundibugyo virus—Democratic Republic of the Congo, August 2026. *MMWR Morb Mortal Wkly Rep* 2026;75:554–6. <https://doi.org/10.15585/mmwr.mm7535e1>

QuickStats

FROM THE NATIONAL CENTER FOR HEALTH STATISTICS

Death Rates* from Unintentional Falls Among Adults Aged ≥ 65 Years, by Sex and Age Group — United States, 2024



* Deaths per 100,000 population.

In 2024, the death rates from unintentional falls among adults aged ≥ 65 years were 74.8 per 100,000 population for men and 66.6 for women. Within each age group, rates were higher for men than for women. Unintentional fall death rates increased with age, with the highest rates among persons aged ≥ 85 years.

Supplementary Table: <https://stacks.cdc.gov/view/cdc/259934#tabs-3>

Source: National Center for Health Statistics, National Vital Statistics System, Mortality Data, 2024. [Underlying Cause of Death, 2018–2024, Single Race](#)

Reported by: Julie D. Weeks, PhD, jad3@cdc.gov; Matthew F. Garnett, MPH.

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the U.S. Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, visit *MMWR* at <https://www.cdc.gov/mmwr/index.html>.

Readers who have difficulty accessing this PDF file may access the HTML file at <https://www.cdc.gov/mmwr/index2026.html>. Address all inquiries about the *MMWR* Series to Editor-in-Chief, *MMWR* Series, Mailstop V25-5, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30329-4027 or to mmwrq@cdc.gov.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

MMWR and *Morbidity and Mortality Weekly Report* are service marks of the U.S. Department of Health and Human Services.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

ISSN: 0149-2195 (Print)